USFDA classifies Aurobindo Pharma Ltd's Unit I as OAI

Aurobindo Pharma Ltd has received a communication from the USFDA classifying the inspection conducted at its Unit I (API) manufacturing facility in Hyderabad, India between August 2 to August 12, 2021 as Official Action Indicated (OAI), keeping the status unchanged.

The Company believes that this inspection classification will not impact the continuing commercial supplies to the US market from this facility.

The Company will be engaging with the regulator and is fully committed in resolving the status of this facility at the earliest.

Shares of Aurobindo Pharma Limited was last trading in BSE at Rs. 676.95 as compared to the previous close of Rs. 672.40. The total number of shares traded during the day was 470367 in over 16263 trades.

The stock hit an intraday high of Rs. 713.25 and intraday low of 673.60. The net turnover during the day was Rs. 326107701.00.

Source : Equity Bulls

Keywords

AurobindoPharmaLimited INE406A01037 AUROPHARMA Pharmaceuticals Unit1 API Hyderabad OAI USFDA